Two Epinastineㆍfour Aprepitant drugs maintain the upper limit
[Newsmp] Starting from September, the South Korean pharmaceutical benefit list will include the diabetes combination drug Envlomet SR Tab. (Daewoong Pharmaceutical), the pompe disease therapy Nexviazyme (Sanofi), the heart failure treatment Verquvo (Bayer), and the growth hormone drug Ngenla (Pfizer).
The following drugs, which were scheduled to have their benefit caps reduced on September 1, will have their original caps maintained: Alesion Eye Drops 0.05% (Santen), Relestat eye drops 0.05% (Allergan), Dukarb Plus Tab. 60/5/25mg (Boryung Pharmaceutical), Emend Cap. 80mg and 125mg (MSD Korea), Atant Cap. 80mg and 125mg (Ace Pharma).
The Ministry of Health and Welfare released a notice reflecting these updates in the Amendment of the drug benefits list and the maximum benefit amount table on August 24.
According to the notice, the maximum price of the SGLT-2 inhibitor and metformin combination drug Envlomet SR Tab. 0.3/1000mg is set at 611 won per tablet.
Nexviazyme will have a reimbursement limit of 1,436,600 won per vial, while Verquvo has a consistent ceiling price of 2,867 won for the 2.5 mg, 5 mg, and 10 mg.
Ngenla Pre-filled Pen is priced at 131,282 won per pen for 24mg and 328,205 won per pen for 60mg.
An additional 50ml (1.23g) will be added for Vitrakvi, in addition to the existing 100ml (2.46g). The reimbursement limit has been set at 24,068 won per bottle, identical to 100ml.
Furthermore, from September 2, a total of 236 single and combination drugs containing sitagliptin (trade name: Januvia) will be newly registered.
Among the existing items, Busulfex Injection (Otsuka Korea) will experience a 30.0% reduction in the reimbursement ceiling on the 1 of next month, followed by an additional 23.5% decrease on August 1 of next year (2024).
On the other hand, from September, the reimbursement prices of Depakote Sprinkle Cap. (Abbott Korea) will be increased by 21.5%, Xenazine Tab. (Korea Orphan & Essential Drug Center) by 19.6%, Leclean Solution (Dongindang Pharmaceutical) by 28.75%, Celltrion Oxymetolone Tab. by 26.0%, Alkyloxan Tab. (JW Pharmaceutical) by 49.0%, and 5-FU Injection Choongwae (JW Pharmaceutical) by 49.6% for 5ml, 49.0% for 10ml, and 51.0% for 20ml.
Moreover, the upper limits for Alesion Eye Drops 0.05%, Relestat eye drops 0.05%, Dukarb Plus Tab. 60/5/25mg, Emend Cap. 80mg and 125mg, and Atant Cap. 80mg and 125mg, which were originally scheduled to have their reimbursement prices reduced on the 1 of next month, will be maintained at their current levels.
However, Alesion Eye Drops 0.05% and Relestat eye drops 0.05% will have their ceilings lowered to the planned limits on September 1 next year (2024), while Dukarb Plus Tab. 60/5/25mg, Emend Cap. 80mg and 125mg, and Atant Cap. 80mg and 125mg will see reductions on September 1, 2025.
The maximum prices of Sitaglu Tab. 25mg, 50mg, and 100mg (Shin Poong Pharmaceutical) will be reduced by 6.8-7.0%, Januvia Tab. 25mg, 50mg, and 100mg by 30.0-30.2%, Janumet XR Tab. 50/1000mg, 50/500mg, and 100/1000mg by 24.0-31.2%, and Stegluzan Tab. 5/100mg (MSD Korea) by 4.3% on September 2. In addition, the amounts of 155 sitagliptin single and combination products, including Januvia and Sitaglu, will be reduced on September 2 of next year.
